Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Background: The bivalent COVID-19 mRNA boosters became available in fall 2022 and were recommended alongside the seasonal influenza vaccine. However, the immunogenicity of concurrent vs separate administration of these vaccines remains unclear.
Methods: Here, we analyzed antibody responses in health care workers who received the bivalent COVID-19 booster and the influenza vaccine on the same day or on different days through systems serology. Antibody-binding and functional responses were characterized at peak responses and after 6 months following vaccination.
Results: IgG1 and neutralization responses to SARS-CoV-2 XBB.1.5 were higher at peak and after 6 months following concurrent administration as compared with separate administration of the COVID-19 and influenza vaccines. While similar results were not observed for influenza responses, no interference was noted with concurrent administration.
Conclusions: These data suggest that concurrent administration of these vaccines may yield higher and more durable SARS-CoV-2 neutralizing antibody responses while maintaining responses against influenza.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 11(2024), 4 vom: 15. Apr., Seite ofae144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barouch, Susanna E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Electronic-eCollection UpdateOf: bioRxiv. 2023 Sep 12;:. - PMID 37745590 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofae144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370566343 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370566343 | ||
| 003 | DE-627 | ||
| 005 | 20240415233640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofae144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM370566343 | ||
| 035 | |a (NLM)38567194 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barouch, Susanna E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concurrent Administration of COVID-19 and Influenza Vaccines Enhances Spike-Specific Antibody Responses |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Sep 12;:. - PMID 37745590 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Background: The bivalent COVID-19 mRNA boosters became available in fall 2022 and were recommended alongside the seasonal influenza vaccine. However, the immunogenicity of concurrent vs separate administration of these vaccines remains unclear | ||
| 520 | |a Methods: Here, we analyzed antibody responses in health care workers who received the bivalent COVID-19 booster and the influenza vaccine on the same day or on different days through systems serology. Antibody-binding and functional responses were characterized at peak responses and after 6 months following vaccination | ||
| 520 | |a Results: IgG1 and neutralization responses to SARS-CoV-2 XBB.1.5 were higher at peak and after 6 months following concurrent administration as compared with separate administration of the COVID-19 and influenza vaccines. While similar results were not observed for influenza responses, no interference was noted with concurrent administration | ||
| 520 | |a Conclusions: These data suggest that concurrent administration of these vaccines may yield higher and more durable SARS-CoV-2 neutralizing antibody responses while maintaining responses against influenza | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a XBB.1.5 | |
| 650 | 4 | |a bivalent | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Chicz, Taras M |e verfasserin |4 aut | |
| 700 | 1 | |a Blanc, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Barbati, Domenic R |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Lily J |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wenjun |e verfasserin |4 aut | |
| 700 | 1 | |a McNamara, Ryan P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 11(2024), 4 vom: 15. Apr., Seite ofae144 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:ofae144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofae144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 4 |b 15 |c 04 |h ofae144 | ||